10th November 2026
Fevertree Drinks plc
(“Fever-Tree” or the "Company")
Transaction in Own Shares
Fevertree Drinks plc (“Fever-Tree” or the “Company”) announces today it has, in accordance with the authority granted by shareholders at its 2025 Annual General Meeting held on 5th June, purchased the following number of ordinary shares of £0.0025 each in the Company (the “Ordinary Shares”) through the Company’s broker, Investec Bank plc (“Investec”) in the period from 2nd November to 6th November 2026.
Date | Venue | Volume-weighted average price (p) | Aggregated volume | Lowest price per share (p) | Highest price per share (p) |
02 November 2026 | XLON | 933.4175 | 35,413 | 922.5000 | 942.5000 |
03 November 2026 | XLON | 931.1475 | 34,446 | 918.0000 | 940.0000 |
04 November 2026 | XLON | 928.7837 | 35,287 | 914.5000 | 936.5000 |
05 November 2026 | XLON | 934.5707 | 34,518 | 924.0000 | 953.5000 |
06 November 2026 | XLON | 918.0973 | 34,952 | 909.0000 | 926.0000 |
The Company intends to cancel the purchased shares.
Schedule of Purchases – Individual Transactions
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law by virtue of the European Union (Withdrawal) Act 2018, as amended), a full breakdown of the individual trades made by Investec on behalf of the Company as part of the share buyback programme is attached to this announcement.
http://www.rns-pdf.londonstockexchange.com/rns/3355C_1-2026-11-9.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
For further information please contact:
Investor queries
Ann Hyams, Director of Investor Relations I ann.hyams@fever-tree.com I +44 7435 828 138
Media queries
Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.